^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | BBT-176 (EGFR inhibitor, Tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BBT-176, a 4th Generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: Updated Report from a Phase 1 Study
Published date:
08/08/2023
Excerpt:
Patients harboring an EGFR mutation who were previously treated with at least one EGFR TKI were enrolled and tested by imaging study and underwent ctDNA analysis every 6 weeks. BBT-176 alone was orally administered either once daily (QD) or twice daily (BID) continuously until progressive disease or intolerability....In addition to previously reported tumor shrinkage cases, signals of tumor shrinkage and molecular response were observed...
